Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Biologic therapy. Chemotherapy. Oregon Health Sciences University, Portkand, OR, United States

Survival: 12.5 months
Toxicity Grade: 4
Treatments: Biologic therapy
Drugs: Emcyt
Country: United States
City/State/Province: Portkand, OR
Hospital: Oregon Health Sciences University
Journal: Link
Date: 9/2005

Patients: This Phase I/II study involved 24 men with metastatic androgen-refractory prostate cancer. Metastatic sites included bone, lymph nodes, and viscera. The median age was 67 years. All patients did not respond to hormone therapy, and thirteen had received prior chemotherapy before the study.

Treatment: The treatment consisted of calcitriol (a form of vitamin D), and two chemotherapeutic agents: , docetaxel, and estramustine.

Toxicity: Grade 3-4 toxicities included neutropenia, hypophosphatemia, and deep vein thrombosis.

Results: The median overall survival was 12.5 months (54 weeks). Of 15 patients who were evaluated, two had a partial response to treatment, and three achieved stable disease.

Support: Aventis Pharmaceuticals financially supported this study, and several authors have financial or business relationships with Aventis. Aventis manufactures and/or markets docetaxel.

Correspondence: Tomasz M. Beer, MD

E-mail to a Friend Email Physician More Information